Vega-Cornejo G, Padilla-Durón N, García-Galaviz A

Language: Spanish
References: 15
Page: 143-148
PDF size: 957.11 Kb.

ABSTRACT

Introduction: Osteopenia is generally considered an adult disease. However, recently it has been observed on diverse studies that its presentation on children has increased. It is considered a problem of public health worldwide since it impacts directly on the economical expenditure of health services and is an important cause of mobility and mortality in our country. The general objective is to determine the prevalence of osteopenia on pediatrics patients suffering a chronic inflammatory disease.
Material and Method: The factors influencing the presentation of osteopenia were analyzed, as well as the disease’s time of evolution variables, treatment, inflammation reactants, electrolytes such as calcium, phosphorus and magnesium, and bone densitometry.
Results: From the 133 files included, 98 did not meet the criteria for inclusion. 35 cases were analyzed; the average age was 10.7 years. It was found a prevalence of osteopenia of 37.1%, 30% were boys and 46.6% girls. The main factor associated with osteopenia was being a man and the disease’s time of evolution.
Conclusion: Osteopenia is a prevalent pathology on pediatrics patients with chronic inflammatory diseases. Its timely detection may offer a treatment and avoid associated complications. It is required studies on a larger population and longer monitoring.

REFERENCES

1. Bishop N, Braillon P, Burnham et al. Dual-energy X-ray absorptiometry assessment in children and adolescents with diseases that may affect the skeleton: the 2007 ISCD Pediatric Official Positions. J Clin Densitom 2008;11:29-42.

2. Bustabad. Osteoporosis infantil. Protoc diagn ter pediatr. 2014; 1: 197-201.

3. Official positions of the International Society for Clinical Densitometry: updated [consultado 17/01/2016]. Disponibleen: http://WWW.iscd,org/visitors/positions/official.cfmwww.i scd,org/visitors/positions/official.cfm

4. Bianchi ML. Osteoporosis in children and adolescents. Bone. 2007;41:486-95.

5. Sosa, Diaz. La osteoporosis. Definición. Importancia. Fisiopatología y Clinica. Rev Osteoporos Metab Miner 2010; 2 (Supl 5): S3-S7.

6. Moral, González. Osteoporosis juvenil. 1ra edición, Manual práctico de osteoporosis y enfermedades del metabolismo mineral, 2004, cap. 49: 273-279.

7. Kwan Tat S, Padrines M, Theoleyre S et al. IL-6, RANKL, TNF-alpha/IL-1: interrelations in bone resor ption pathophysiology. Cytokine Growth Factor Rev 2004;15:49-60.

8. Paganelli M, Albanese C, Borrelli O et al. Inflammation is the main determinant of low bone mineral density in pediatric inflammatory bowel disease. Inflamm Bowel Dis 2007; 13:416- 23.

9. Baroncelli G, Bertelloni S, Sodini F, Saggese G. Osteoporosis in children and adolescents: etiology and management. Paediatr Drugs. 2005;7: 295-323.

10. Falcini F, Bindi G, Simonini G et al. Bone status evaluation with calcaneal ultrasound in children with chronic rheumatic diseases. A one year followup study. J Rheumatol. 2003;30:179- 84.

11. Espada, Malagon, Rosé. Osteoporosis en la infancia. 1ra edición, Manual Práctico de Reumatologia Pediatrica, 2006, cap.8: 393-398.

12. Leonard MB. Glucocorticoid-induced osteoporosis in children: impact of the underlying disease. Pediatrics 2007;119(Suppl 2):S166-74.

13. Huber AM, Gaboury I, Cabral DA et al. Prevalent vertebral fractures among children initiating glucocorticoid therapy for the treatment of rheumatic disorders. Arthritis Care Res. 2010;62:516-26.

14. NIH Consensus Development Panel on Osteoporosis Prevention D, and Therapy. Osteoporosis prevention, diagnosis, and therapy. JAMA 2001;285:785-95.

15. K. Bachrach, M. Ward, Clinical Review: Bisphosphonate Use in Childhood Osteoporosis. J Clin Endocrinol Metab. February 2009, 94(2):400-409.